Therapeutic window, a critical developmental stage for stem cell therapies

Current Stem Cell Research and Therapy

Volumn 5, Issue 4, 2010, Pages 287-293

  Li, Shengwen Calvin ^a,b   Han, Yuan Ping ^c   Dethlefs, Brent A ^a   Loudon, William G ^a,b  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Pediatric brain tumor; Stem cells; Therapy; Tumor targeting

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GELATINASE B; STROMAL CELL DERIVED FACTOR 1; CYTOKINE;

ARTICLE; BIOASSAY; BRAIN CANCER; CANCER INHIBITION; CANCER MORTALITY; CANCER SURVIVAL; CELL SUBPOPULATION; CHILD; CHILDHOOD CANCER; CHILDHOOD MORTALITY; COGNITIVE DEFECT; GLIOBLASTOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; ANIMAL; BIOLOGICAL MODEL; BRAIN TUMOR; CELL DIFFERENTIATION; CELL LINEAGE; CELL MOTION; DISEASE MODEL; DRUG DELIVERY SYSTEM; GLIOMA; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINEAGE; CELL MOVEMENT; CHILD; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; MODELS, BIOLOGICAL; STEM CELL TRANSPLANTATION; TUMOR MICROENVIRONMENT;

EID: 77958149635     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488810793351730     Document Type: Article

References (44)

1. Li SC, Loudon WG. A novel and generalizable organotypic slice platform to evaluate stem cell potential for targeting pediatric brain tumors. Cancer Cell Int 2008; 8: 1-11.
2. Legler JM, Ries LAG, Smith MA, et al. Brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999; 91(16): 1382-90.
3. Surawicz TS, Davis F, Freels S, Laws ER, Menck HR. Brain tumor survival: Results from the National Cancer Data Base. J Neurooncol 1998; 40(2): 151-60.
4. Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res 2010; 70(8): 3005-8.
5. Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG, Redmond HP. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003; 4(12): 760-8.
6. Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004; 22(16): 3357.
7. Amann M, Brischwein K, Lutterbuese P, et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 2008; 68(1): 143-51.
8. Bellavance MA, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J 2008; 10(1): 166-77.
9. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307(5706): 58-62.
10. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev 2007; 8(8): 610-22.
11. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007; 67(6): 2729-35.
12. Hall WA. Targeted toxin therapy for malignant astrocytoma. Neurosurgery 2000;46(3):544.
13. Attard-Montalto S, Plowman N, Breatnach F, Saha V, Eden OB. Is there a danger in delaying radiotherapy in childhood medulloblastoma? Br J Radiol 1993; 66(789): 807.
14. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cellmediated tumor selective gene therapy. Gene Ther 2008; 15(10): 739-52.
15. Li SC, Loudon WG. Stem cell therapy for paediatric malignant brain tumours: the silver bullet? ONcology News (UK), June-July 2008, ISSN 1751-4975. 2008; 3(1): 10-4. http://www.oncologynews.biz/pdf/jun_jul_08/ONJJ_stemcell.pdf (Accessed May 4, 2008).
16. Mapara KY, Stevenson CB, Thompson RC, Ehtesham M. Stem cells as vehicles for the treatment of brain cancer. Neurosurg Clin N Am 2007; 18(1): 71-80, ix.
17. Muller FJ, Snyder EY, Loring JF. Gene therapy: can neural stem cells deliver? Nat Rev Neurosci 2006 01; 7(1): 75-84.
18. Ben-Hur T. Human embryonic stem cells for neuronal repair. Isr Med Assoc J 2006; 8(2): 122-6.
19. Chen HI, Bakshi A, Royo NC, Magge SN, Watson DJ. Neural stem cells as biological minipumps: a faster route to cell therapy for the CNS? Curr Stem Cell Res Ther 2007; 2(1): 13-22.
20. Phinney DG. Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell Cycle 2007; 6(23): 2884-9.
21. Phinney DG, Baddoo M, Dutreil M, Gaupp D, Lai WT, Isakova IA. Murine mesenchymal stem cells transplanted to the central nervous system of neonatal versus adult mice exhibit distinct engraftment kinetics and express receptors that guide neuronal cell migration. Stem Cells Dev 2006; 15(3): 437-47.
22. Phinney DG, Hill K, Michelson C, et al. Biological activities encoded by the murine mesenchymal stem cell transcriptome provide a basis for their developmental potential and broad therapeutic efficacy. Stem Cells 2006; 24(1): 186-98.
23. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells 2007; 25(11): 2896-902.
24. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009; 6(2): e1000029.
25. Sagar J, Chaib B, Sales K, Winslet M, Seifalian A. Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int 2007; 7: 9.
26. Weidt C, Niggemann B, Kasenda B, Drell TL, Zanker KS, Dittmar T. Stem cell migration: a quintessential stepping stone to successful therapy. Curr Stem Cell Res Ther 2007; 2(1): 89-103.
27. Weidt C, Niggemann B, Hatzmann W, Zanker KS, Dittmar T. Differential effects of culture conditions on the migration pattern of stromal cell-derived factor-stimulated hematopoietic stem cells. Stem Cells 2004; 22(6): 890-6.
28. Imitola J, Raddassi K, Park KI, et al. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci USA 2004; 101(52): 18117-22.
29. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97(23): 12846-51.
30. Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 2007; 109(9): 4055-63.
31. Sordi V, Malosio ML, Marchesi F, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005; 106(2): 419-27.
32. Wynn RF, Hart CA, Corradi-Perini C, et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004; 104(9): 2643-5.
33. Dekel B, Burakova T, Arditti FD, et al. Human and porcine early kidney precursors as a new source for transplantation. Nat Med 2003; 9(1): 53-60.
34. Dekel B, Reisner Y. Embryonic committed stem cells as a solution to kidney donor shortage. Expert Opin Biol Ther 2004; 4(4): 443-54.
35. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282(5391): 1145-7.
36. Eventov-Friedman S, Katchman H, Shezen E, et al. Embryonic pig liver, pancreas, and lung as a source for transplantation: optimal organogenesis without teratoma depends on distinct time windows. Proc Natl Acad Sci USA 2005; 102(8): 2928-33.
37. Eventov-Friedman S, Tchorsh D, Katchman H, et al. Embryonic pig pancreatic tissue transplantation for the treatment of diabetes. PLoS Med 2006; 3(7): e215.
38. Penn MS, Zhang M, Deglurkar I, Topol EJ. Role of stem cell homing in myocardial regeneration. Int J Cardiol 2004; 95 (Suppl 1): S23-S5.
39. Brederlau A, Correia AS, Anisimov SV, et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkin son's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006; 24(6): 1433-40.
40. Jiang J, Au M, Lu K, et al. Generation of insulin-producing isletlike clusters from human embryonic stem cells. Stem Cells 2007; 25(8): 1940-53.
41. Condomines M, Veyrune JL, Larroque M, et al. Increased plasmaimmune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy. J Immunol 2010; 184 (2): 1079-84.
42. Dillmann F, Veldwijk MR, Laufs S, et al. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Leuk Lymphoma 2009; 50(10): 1676-86.
43. Munson S, Schroth E, Ernst M. The Role of Functional Neuroimaging in Pediatric Brain Injury. Pediatrics 2006; 117(4): 1372-81.
44. Li SC, Tachiki LM, Luo J, Dethlefs BA, Chen Z, Loudon WG. A biological global positioning system: considerations for tracking stem cell behaviors in the whole body. Stem Cell Rev 2010; 6(2): 317-33.